

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – July 5, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on July 5, 2023, from Atlas Special Opportunities LLC indicating that as of June 16, 2023, it held 29,426,983 shares of the then outstanding 1,202,394,457 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

Oxurion received a transparency notification on July 5, 2023, from Atlas Special Opportunities LLC indicating that as of June 21, 2023, it held 75,981,349 shares of the then outstanding 1,265,917,890 shares, and therefore crossed above the threshold (5%) by virtue of the acquisition of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

tom.graney@oxurion.com

Oxurion NV US

Tom Graney <u>Conway Communications</u>

Chief Executive Officer Mary T. Conway

Tel: +32 16 75 13 10 mtconway@conwaycommsir.com

Michael Dillen


Chief Business Officer

ICR Westwicke
Christopher Brinzey

Chief Business Officer Christopher Brinzey
Tel: +32 16 75 13 10 Tel: +1 617 835 9304

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1



9) Denominator

1,202,394,457

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction				
		# of voti	ng rights	% of voting rights		
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Atlas Special Opportunities LLC	43,678,292	29,426,983	,	2.45%		
то	TAL	29,426,983	0	2.45%	0.00%	

For groups, start with the ultimate controlling natural person or legal entity.

The totals, subtotals and % will be updated once you have clicked on *CALCULATE>.

1 Envelope ID: 30B8EDE6-FCEE-4E2E-9788-454D19362F65

) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TC	OTAL			0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights	
	CALCULATE	29,426,983	2.45%	

+

12) In case of proxy voting for only one GM Will cease to hold / will hold again 13) Additional information Alias Special Opportunities LLC sold 14.251.309 shares in Oxurion NV, as a result of which its shareholding decreased to 29.426.983 shares (= 2.45%) (denominator = 1.202.394.457 shares).


22/06/2023 (DD/MM/YYYY)

Patrick Vance

Done at New York

Name & capacity Patrick Vance, proxyholder

ANNEX 2



9) Denominator

1,265,917,890

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	29,426,983	75,981,349		6.00%	
•	TOTAL	75,981,349	0	6.00%	0.00%



n Envelope ID: 796AC54B-EE3E-46EA-B6D9-A2C78E254274

B) Equivalent financial instruments	After the transaction						
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
							+
	TOTAL			0	0.00%		

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	75,981,349	6.00%

12) In case of proxy voting for only one GM Holder will cease to hold / will hold again 13) Additional information On 19/06/2023 Alias Special Opportunities LLC sold 465,501 shares in Oxurion NV, as a result of which its shareholding decreased to 28,941,482 shares (= 2.41%) (denominator = 1,202,394,457), On 21/06/2023 Alias Special Opportunities LLC sold 41,313,744 shares, as a result of which its shareholding increased to 14,627,738 shares (= 1,22%) (denominator = 1,202,394,457), On 21/06/2023 Alias Special Opportunities LLC sold 42,169,822 shares and converted 63,523,433 shares, as a result of which its shareholding increased to 14,627,738 shares (= 1,22%) (denominator = 1,202,394,457), On 21/06/2023 Alias Special Opportunities LLC sold 2,169,822 shares and converted 63,523,433 shares, as a result of which its shareholding increased to 75,981,349 shares (= 6,00%) (denominator = 1,265,917,890).

23/06/2023 (DD/MM/YYYY)

Signature Patrick Vance

Done at New York

Name & capacity Patrick Vance, proxyholder